Volatile organic compound-based diagnostic systems and methods

Patent metadata

Field	Value
Publication number	US-11415546-B2
Application number	US-201515501338-A
Country	US
Kind code	B2
Filing date	Sep 3, 2015
Priority date	Sep 5, 2014
Publication date	Aug 16, 2022
Grant date	Aug 16, 2022

Abstract

Provided are devices and methods to detect the presence of volatile organic compounds related to the presence of a disease state in a biological sample. The devices may include a detection moiety such as a polynucleotide in electronic communication with a semiconductor such as graphene or a carbon nanotube.

First claim

What is claimed:

1. A detection device, comprising:
a substrate having a surface;
a semiconductor and a detection moiety in electronic communication with one another,
the detection moiety comprising a polynucleotide that includes one or more of 5′ CCC GTT GGT ATG GGA GTT GAG TGC 3′ (SEQ ID NO: 3) and 5′ GTA CGG ACT GTG AAT GCG CGT TAG 3′ (SEQ ID NO: 4),
the substrate supporting the semiconductor and the semiconductor being arranged substantially parallel to the surface of the substrate,
the detection moiety being configured to detect one or more volatile organic compounds present in a biological sample; and
a sensor chamber configured to retain therein the one or more volatile organic compounds present in the biological sample,
the device being configured such that the detection moiety is capable of fluid communication with the interior of the sensor chamber.

2. The device of claim 1 , wherein the semiconductor comprises graphene, a carbon nanotube, MoS 2 , zinc oxide, WS 2 , silicon germanium, gallium arsenide, indium phosphide, gallium nitride, or any combination thereof.

3. The device of claim 1 , wherein the detection moiety comprises a polypeptide.

4. The device of claim 1 , wherein the one or more volatile organic compounds comprises dimethylsulfone, 3,4-dimethyl benzaldehyde, an alkyl substituted pyridine, cyclohexanone, 2-pentylfuran, caprolactam, or any combination thereof.

5. The device of claim 1 , wherein the device comprises a monitor configured to detect a signal, a change in signal, or both related to an interaction between the detection moiety and a volatile organic compound of a biological sample.

6. The device of claim 1 , wherein the detection moiety is bound to the semiconductor by pi-pi orbital interaction.

7. The device of claim 1 , wherein the device further comprises a heater configured to heat the interior of the sensor chamber.

8. The device of claim 1 , wherein the device further comprises a source of salt configured for addition to the biological sample.

9. The device of claim 1 , wherein the device comprises two electrodes and wherein the semiconductor is disposed in a conductive path that places the two electrodes into electronic communication with one another.

10. The device of claim 1 , wherein the sensor chamber defines a headspace within, and wherein the detection moiety is disposed within the headspace.

11. The device of claim 1 , further comprising a vacuum device configured to encourage release of one or more volatile organic compounds present in the biological sample.

12. A method, comprising:
(i) exposing a device comprising:
a semiconductor and a detection moiety in electronic communication with one another,
the detection moiety comprising a polynucleotide that includes one or more of 5′ CCC GTT GGT ATG GGA GTT GAG TGC 3′ (SEQ ID NO: 3) and 5′ GTA CGG ACT GTG AAT GCG CGT TAG 3′ (SEQ ID NO: 4),
the detection moiety being configured to detect one or more volatile organic compounds present in a biological sample, and
a sensor chamber,
the device being configured such that the detection moiety is capable of fluid communication with the interior of the sensor chamber,
to an atmosphere above a biological sample from a patient, the atmosphere comprising one or more volatile organic compounds of the sample; and
(ii) detecting a signal, a change in signal, or both related to exposing the device to the atmosphere.

13. The method of claim 12 , further comprising adding a material to the biological sample that encourages one or more volatile organic compounds from the sample into the atmosphere, heating the biological sample, applying a reduced pressure to the biological sample, or any combination thereof.

14. The method of claim 13 , wherein the material comprises a salt.

15. The method of claim 12 , wherein the change in signal comprises a change in current, a change in voltage, a change in resistance, a change in intensity, a change in wavelength, or any combination thereof.

16. The method of claim 12 , further comprising correlating the signal, the change in signal, or both, to a disease state of the patient.

17. The method of claim 16 , wherein the disease state comprises cancer.

18. The method of claim 16 , wherein the correlating comprises comparing the signal, change in signal, or both to a signal, a change in signal, or both to a standard.

19. The method of claim 18 , wherein the standard comprises a well patient.

20. The method of claim 18 , wherein the standard comprises a disease state patient.

Assignees

• Univ Pennsylvania
• Monell Chemical Senses Centre

Inventors

• Johnson Alan T
• Kybert Nicholas J
• Preti George
• Prigge Katharine A
• Tanyi Janos L
• Otto Cynthia

Classifications

• G01N33/57545

  of the ovaries · CPC title

• G01N2800/7028

  Cancer · CPC title

• G01N27/4146 Primary

  involving nanosized elements, e.g. nanotubes, nanowires · CPC title

• B82Y30/00

  Nanotechnology for materials or surface science, e.g. nanocomposites · CPC title

• G01N33/5308

  for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites · CPC title